Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation
about
Intracellular targeting with engineered proteinsTumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RASConformational flexibility of the oncogenic protein LMO2 primes the formation of the multi-protein transcription complexA cancer specific cell-penetrating peptide, BR2, for the efficient delivery of an scFv into cancer cellsSingle domain intrabodies against WASP inhibit TCR-induced immune responses in transgenic mice T cells.De novo production of diverse intracellular antibody libraries.Antibodies as therapeutic agents: vive la renaissance!Identification and characterization of tumor antigens by using antibody phage display and intrabody strategies.A focused antibody library for selecting scFvs expressed at high levels in the cytoplasm.Selection of complementary single-variable domains for building monoclonal antibodies to native proteinsVersatile selection technology for intracellular protein-protein interactions mediated by a unique bacterial hitchhiker transport mechanismCost-effective HRMA pre-sequence typing of clone libraries; application to phage display selectionProtocol for the selection of single-domain antibody fragments by third generation intracellular antibody capture.Single domain intracellular antibodies from diverse libraries: emphasizing dual functions of LMO2 protein interactions using a single VH domainTargeting Pyk2 for therapeutic interventionSingle-domain antibodies and their utility.The Pyk2 FERM domain as a target to inhibit glioma migration.Generation of a single chain antibody variable fragment (scFv) to sense selectively RhoB activation.Potential applications of intracellular antibodies (intrabodies) in stem cell therapeutics.Single domain antibodies for the knockdown of cytosolic and nuclear proteins.State of the art in tumor antigen and biomarker discovery.Targeting antibodies to the cytoplasm.Intracellular antibodies and cancer: new technologies offer therapeutic opportunities.Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange.Intracellular Crosslinking of Filoviral Nucleoproteins with Xintrabodies Restricts Viral Packaging.A novel strategy for specifically down-regulating individual Rho GTPase activity in tumor cells.Identification of a GTP-bound Rho specific scFv molecular sensor by phage display selection.Protein silencing with Phylomers: a new tool for target validation and generating lead biologicals targeting protein interactions.Chromosomal translocation engineering to recapitulate primary events of human cancer.BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions.Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment
P2860
Q26740106-B1C4E82A-450B-47F0-B3A4-0E37D9A0DC75Q27645826-5282681A-F1A6-4BEC-907E-2EECFA5BD65DQ27681258-6BEDFBFC-4DF5-4DCF-A85C-AACDD5A34416Q28533791-C0CFF58B-771C-44AE-AB2B-58C9F46BE748Q30009538-5EDC6D16-CAD2-46E5-B9B9-6A67A2C78086Q30887786-127AA09B-A831-4D36-98DF-F76537C1E78EQ33193524-AB283DBF-36C0-4FDB-B0A4-BC03DDA32774Q33284494-AB0D8DCA-DC85-45B6-BB13-B27FDD644DE0Q33307001-85ED568C-D424-4DA4-B911-8BE88BEDC708Q33408086-6FEA1F5B-E212-4D4B-B749-B20429CFEC58Q33411263-FEBD714F-5AB1-4291-B649-494B805AD9F3Q33450995-8C83A5FC-18FD-449D-9A8B-164FCCA35E34Q33522558-D772EE7A-3ABE-4FBA-9F1E-9CB1EB800C48Q33729971-6B804214-5957-4EB5-9EE7-70BBAE93376CQ34146883-51596C07-2998-4E07-82E1-79ED48C8EC1AQ35089545-50BD9D54-18BB-4362-BE0D-CA1E4E8F0FF1Q35234199-A6BFBAE7-68D7-491D-A9E9-4EB4E39C285DQ35388015-1C638BFB-419B-4118-A48F-8313B4C30357Q36077406-673DA619-E752-46BD-BB4F-532EF89DFA6CQ36300378-E6810DB1-9F30-4793-8F50-2E5CC096895EQ37132800-28B390E0-3F75-46A4-8F0A-BC7D6CF0936AQ37811739-E7183F73-8A72-444F-BC99-D6950B22E2A9Q39864280-C3D069EE-42A9-4921-8291-CA96729EBEDBQ41077398-A7261BD2-753A-41D0-9F1B-733EF2804E31Q41918644-FF7D0D39-5C67-470A-8F01-E6879347374AQ42797811-2E97F582-B0B9-4046-80D5-6828A4169B71Q43151828-9161750E-A804-44A5-92BB-00332084293EQ50923792-631B4957-420D-4122-AD31-6C9F1B185121Q51155518-2FCE252A-7E68-45A5-8A40-025154BCFDC7Q55618585-D49E69EB-5E60-4ACA-AE43-A0D34FCACC82Q58046152-B341E021-C0B1-4A31-999C-CE9ADBFE4136
P2860
Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Intrabodies based on intracell ...... mpair oncogenic transformation
@ast
Intrabodies based on intracell ...... mpair oncogenic transformation
@en
Intrabodies based on intracell ...... mpair oncogenic transformation
@en-gb
Intrabodies based on intracell ...... mpair oncogenic transformation
@nl
type
label
Intrabodies based on intracell ...... mpair oncogenic transformation
@ast
Intrabodies based on intracell ...... mpair oncogenic transformation
@en
Intrabodies based on intracell ...... mpair oncogenic transformation
@en-gb
Intrabodies based on intracell ...... mpair oncogenic transformation
@nl
prefLabel
Intrabodies based on intracell ...... mpair oncogenic transformation
@ast
Intrabodies based on intracell ...... mpair oncogenic transformation
@en
Intrabodies based on intracell ...... mpair oncogenic transformation
@en-gb
Intrabodies based on intracell ...... mpair oncogenic transformation
@nl
P2860
P356
P1433
P1476
Intrabodies based on intracell ...... mpair oncogenic transformation
@en
P2093
Tomoyuki Tanaka
P2860
P304
P356
10.1093/EMBOJ/CDG106
P407
P577
2003-03-01T00:00:00Z